Olaparib for BRCA-Mutated Ovarian Cancer: Andrés Poveda, MD

Last weekend, in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, Andrés Poveda, MD, presented results of the phase 3 SOLO2/ENGOT Ov-21 trial, reporting that olaparib significantly increased median overall survival compared with placebo in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In this interview with i3 Health, Dr. Poveda, Executive Co-Director of Initia Oncology in Valencia, Spain, discusses the significance of the trial's results...
Continue reading

Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma: John Kuruvilla, MD

This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial, reporting that pembrolizumab significantly increased progression-free survival compared with brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma. In this interview with i3 Health, Dr. Kuruvilla, an Associate Professor of Medicine at the University of Toronto, discusses the challenges of treatin...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.